Literature DB >> 8846426

Central tachykinins: mediators of defence reaction and stress reactions.

J Culman1, T Unger.   

Abstract

The tachykinins substance P, neurokinin A, and neurokinin B are natural agonists for NK1, NK2, and NK3 receptors, respectively. Evidence from biochemical, neurophysiological, pharmacological, and molecular biology studies indicates that the tachykinin-containing pathways within the brain contribute to central cardiovascular and endocrine regulation and to the control of motor activity. The hypothalamus, which represents a site for the integration of central neuroendocrine and autonomic processes, is rich in tachykinin nerve endings and tachykinin receptors. Stimulation of periventricular or hypothalamic NK1 receptors in conscious rats induces an integrated cardiovascular, behavioural, and endocrine response. The cardiovascular response is associated with increased sympathoadrenal activity and comprises an increase in blood pressure and heart rate, mesenteric and renal vasoconstriction, and hind-limb vasodilatation. The behavioural response consists of increased locomotion and grooming behaviour. This response pattern is consistent with an integrated stress response to nociceptive stimuli and pain in rodents. Several studies have demonstrated rapid changes in substance P levels and its receptors in distinct brain areas following acute stress. These data indicate that substance P and other tachykinins, in addition to serving as nociceptive and pain transmitters in the spinal cord, may act in the brain as neurotransmitters--neuromodulators within the neuronal circuits mediating central stress responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846426     DOI: 10.1139/y95-122

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  17 in total

1.  Connections of the lateral hypothalamic area juxtadorsomedial region in the male rat.

Authors:  Joel D Hahn; Larry W Swanson
Journal:  J Comp Neurol       Date:  2012-06-15       Impact factor: 3.215

2.  The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.

Authors:  Kathleen Deschamps; Réjean Couture
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

3.  Advances in the Management of Treatment-Resistant Depression.

Authors:  Paul E Holtzheimer
Journal:  Focus (Am Psychiatr Publ)       Date:  2010

4.  Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis.

Authors:  D Singh; D D Joshi; M Hameed; J Qian; P Gascón; P B Maloof; A Mosenthal; P Rameshwar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

5.  Modulation of cardiac activity by tachykinins in the rat substantia nigra.

Authors:  A Lessard; R Couture
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Substance P-saporin lesion of neurons with NK1 receptors in one chemoreceptor site in rats decreases ventilation and chemosensitivity.

Authors:  Eugene E Nattie; Aihua Li
Journal:  J Physiol       Date:  2002-10-15       Impact factor: 5.182

Review 7.  Novel targets for antidepressant therapies.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

Review 8.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10

Review 9.  Advances in the treatment of depression.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  NeuroRx       Date:  2006-01

Review 10.  Emerging targets for antidepressant therapies.

Authors:  Jeffrey J Rakofsky; Paul E Holtzheimer; Charles B Nemeroff
Journal:  Curr Opin Chem Biol       Date:  2009-06-06       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.